Snider Financial Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-46,214
Closed -$5.33M 70
2021
Q4
$5.33M Buy
46,214
+1,946
+4% +$235K 2.26% 18
2021
Q3
$5.53M Buy
44,268
+6,125
+16% +$789K 2.41% 17
2021
Q2
$4.8M Buy
+38,143
New +$5.01M 2.26% 17

Other funds holding XBI

Snider Financial Group's XBI Position: Q1 2022 in Review

Snider Financial Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 46,214 shares — an estimated $5.33M sold.

Snider Financial Group first reported a position in XBI in Q2 2021 and held it in 3 quarters. The position peaked at $5.53M in Q3 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

  • Snider Financial Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
  • Snider Financial Group sold 46,214 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $5.33M.
  • Snider Financial Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 3 quarters.
  • Snider Financial Group's State Street SPDR S&P Biotech ETF position peaked at $5.53M in Q3 2021.
  • 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Snider Financial Group's 13F filing for Q1 2022, filed 13 May 2022.